3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Hepatocellular
2
Uveal Melanoma
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Neoplasms
1
Leukemia, Myeloid, Acute
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma
1
Advanced Solid Cancers
1
Interventions
Temozolomide
22
Bevacizumab
10
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Irinotecan
5
Carmustine
4
fluorodopa F 18
3
Topotecan
3
Surgical Procedures, Operative
3
Standard of Care
3
Radiosurgery
3
Magnetic Resonance Imaging
3
Congresses as Topic
3
Carboplatin
3
Aminolevulinic Acid
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
ribociclib
2
poly ICLC
2
fluoromisonidazole
2
carmustine, poliferprosan 20 drug combination
2
cabozantinib
2
Vorinostat
2
TIC10 compound
2
Re-Irradiation
2
Radiotherapy, Intensity-Modulated
2
Panobinostat
2
O(6)-benzylguanine
2
Melphalan
2
Lomustine
2
Lacosamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Glioma
×
ADI PEG20
×
Clear all
NCT02029690
2020-09-25
TRAP
Polaris Group
Phase 1
Terminated
85 enrolled